-Live Mint Subsidized loans given to farmers through KCCs could very well be the next big source of NPAs for banks Mumbai: A surge in exposure to farm debt through Kisan Credit Cards (KCCs) could emerge as a risk for India's state-run banks, according to experts. Subsidized loans are given to farmers through KCCs by state-owned banks. Until March 2012, the outstanding amount on such loans was`1.6 trillion through 20.3 million cards, as...

-PTI State tweaked rules to grant land to Ford and L&T, says report The Comptroller and Auditor-General of India has come down heavily on the Gujarat government and State public sector undertakings for causing a loss of nearly Rs. 580 crore to the exchequer by bestowing "undue" favours on large corporate entities. Major industrial houses to which the Narendra Modi government played benefactor included Reliance Industries Ltd (RIL), Essar Steel and Adani Power...

-The Business Standard CAG says GSPL did not safeguard its own Interest leading to passing on of undue benefit of Rs 52 cr to RIL In what could add more teeth to the opposition party's allegations against the Narendra Modi-led Gujarat government, the Comptroller and Auditor General of India (CAG)'s latest report has brought out fresh details of undue favour by state public sector undertakings (PSUs) to Reliance Industries Limited (RIL) and...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...